<DOC>
	<DOCNO>NCT03072277</DOCNO>
	<brief_summary>DHANI-2 extension DHANI ( NCT01580345 ) propose extend maternal supplementation ( DHA Placebo ) &lt; 20 week gestational age 6 month postpartum infant follow-up 12 month . Leveraging RCT design , DHANI-2 aim assess role maternal DHA supplementation infant neurodevelopment body growth . It also intend enhance mechanistic understanding addition repeat biochemical measure mother-child dyad .</brief_summary>
	<brief_title>Maternal DHA Supplementation Offspring Neurodevelopment India ( DHANI-2 )</brief_title>
	<detailed_description>A double-blinded , randomize , placebo control trial would conduct among pregnant woman India test effectiveness supplement pregnant Indian woman 400 mg/d algal DHA compare placebo mid-pregnancy delivery . Eligible participant would randomize receive either 400 mg DHA placebo baseline measure would take enrollment participant study . The mother-child dyad would follow infant age 1 year anthropometric measurement biochemical investigation would use assess effect maternal DHA supplementation infant neurodevelopment age 6- 12-months use validated Development Assessment Scale Indian Infants ( DASII ) .</detailed_description>
	<criteria>18 35 year old pregnant woman ( singleton ) &lt; =20 week gestation ( calculate LMP study physician ) . Willing participate study perform measurement self , husband offspring include anthropometry , dietary assessment , questionnaires biological sample ( blood breast milk ) . Willing provide sign date informed consent . Women allergic ( aware ) test product . Women high risk hemorrhagic bleeding , clot ( aware ) . Women highrisk pregnancy ( history prevalence pregnancy complication , include abruptio placenta , preeclampsia , pregnancyinduced hypertension , serious bleed episode current pregnancy , and/ physician referral ) ; and/or diagnose chronic degenerative disease ( ) diagnose heart disease , cancer , stroke diabetes ( omega3 could raise blood sugar low insulin production ) . Women consume omega3 supplement use 3 month precede intervention period . Reported participation another biomedical trial 3 month start study study ( get result present study contaminate ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DHA</keyword>
	<keyword>Docosa Hexaenoic Acid</keyword>
	<keyword>Omega 3 fatty acid</keyword>
	<keyword>Newborn Outcome</keyword>
	<keyword>Birth Size</keyword>
	<keyword>Gestational Age</keyword>
	<keyword>DASII</keyword>
	<keyword>Prenatal Supplementation</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Neurodevelopment</keyword>
</DOC>